Government Affairs
Health and Life Sciences
Contact Us
Need a problem solved?
Let’s work together to solve it. Request a free consultation from our team of dedicated experts with offices based around the globe.
The Opportunity
Our client, a global pharmaceutical company with a pioneering monoclonal antibody (mAb) for respiratory syncytial virus (RSV), sought to raise awareness of the virus’s public health burden and engage governments on integrating innovative immunisation tools into national programmes. The client needed a platform to introduce RSV prevention as a regional priority and support market access for their innovation.
The Solution
Access Partnership secured APEC sponsorship for the project from both Chile and the United States, creating a credible pathway for policy engagement. We organised and moderated two hybrid policy dialogues – including one held as an official APEC side event in Korea – to elevate RSV on the regional agenda. These dialogues helped shape clear takeaways and next steps for stakeholders, resulting in the formation of multistakeholder advisory groups in several markets to explore the value of the antibody and address barriers to its approval and uptake.
The Impact
- Elevated RSV prevention to a recognised regional policy issue within APEC
- Catalysed multistakeholder engagement on market access in multiple regions
- Positioned the client as a leader in advancing next-generation solutions for public health challenges
Share
